ASH 2023 | NHL33 ‘WAMM’ study: sandwich approach of acalabrutinib plus rituximab and chemotherapy & ASCT in MCL

Eliza Hawkes, FRACP, MD, MBBS, The Olivia Newton-John Cancer Wellness & Research Centre at Austin Health, Melbourne, Australia, gives an overview of the first report of data coming from an investigator-initiated study in fit patients with treatment-naïve mantle cell lymphoma (MCL) who were treated with acalabrutinib (A) and rituximab (R), followed by RDHAOx chemotherapy (rituximab, dexamethasone, cytarabine, oxaliplatin) with or without autologous stem cell transplantation (ASCT), and subsequent fixed-duration AR-maintenance. The NHL33 ‘WAMM’ (ACTRN12619000990123) trial is a multicentre single-arm Phase II trial and is the first Australian blood cancer trial to use telehealth and a ‘hub-and-spoke’ transplant model, which sped up recruitment and improved treatment access for patients living in rural locations, respectively. The study showed that acalabrutinib and rituximab in a sandwich approach is an active and well-tolerated regimen in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.